* PHARMALEADS *
2000 - IDF
Paris
www.pharmaleads.com Design, Drugs
(also, Discovery, Drugs)
Key words: Enzymes, Zinc Metallopeptidases, Substrates, Inhibitors, Fluofast, Analgesia
Mission: to develop custom design of substrates and inhibitors of all types of proteases for three main applications, on-demand design of optimised substrates and/or inhibitors for pharmaceutical companies, internal drug discovery in the field of analgesia, leading services in botulinum toxin detection and assay
Clients: Research labs, Pharmaceutical industry
info@pharmaleads.com
Age: 11 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Personal venture |
Managing Dir.-CEO: Bourbié (Thierry) [born 1952, Polytechnique-Mines, Ph.D. Geophysics, ex-Suez, Schlumberger]
Sc.Dir.-CSO: Roques (Bernard Pierre) [Ph.D., ex-Inserm, Polytechnique (Assistant Prof.)]
Fin.Dir.-CFO: Maillard (Pierre) [MBA-ESSEC, ex-Dassault Aviation, Suez Environment]
BusDev: Wurm (Michel) [M.D.]
Financers (Hist.): undisclosed | Turnover (M€) : 4.79 (2009), 8.26 (2008), 0.43 (2006)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Multiple
Position : Trade
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 2008 .11 | Licensing-out of analgesic PL37 to Debiopharm (Switzerland), beginning phase I, with € undisclosed Millions upfront payment | LICOUT | [7 years] |
| 2008 .10 | Clinical trial (phase I) for PL 37, own analgesic drug (beginning) | CLIN | [7 years] |
| 2006 .04 | Launch of new Fluofast high fluorescence library of peptide enzymes | MKTG | [5 years] |
| 2005 .01 | Management reshuffling : managers replacing scientific founders in operations | ORG | [4 years] |
| 2000 .12 | Company founded by a group of Inserm researchers led by Bernard Roques (Pharm.D., Ph.D. Physico-chemistry) and Marie-Claude Fournié-Zaluski (CEO, Ph.D. Chemistry) | ORGF | [0 year] | Actualisation / Updating: 3-May-2011 |
|
